SRTS SENSUS HEALTHCARE

Sensus Healthcare Announces CME Presentation by Dr. Jeffrey S. Fromowitz Today at the Fall Clinical Virtual Grand Rounds Series

Sensus Healthcare Announces CME Presentation by Dr. Jeffrey S. Fromowitz Today at the Fall Clinical Virtual Grand Rounds Series

BOCA RATON, Fla, June 24, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Jeffrey S. Fromowitz, M.D. will discuss the use of superficial radiation therapy at the Fall Clinical Virtual Grand Rounds Weekly Continuing Education Series today.  The presentation is part of the recent online series titled “Evolving Concepts in Dermatology; Dermatology Industry LeadersThe Path Forward” and participants will receive continuing medical education (CME) credits.

Dr. Fromowitz’s discussion will focus on the use of superficial radiation therapy to treat non-melanoma skin cancers, as well as keloids.

Dr. Fromowitz is a board-certified dermatologist with advanced training in Mohs micrographic surgery and cosmetic dermatology. Practicing in Boca Raton, Florida, Dr. Fromowitz serves as the medical director of Dermatology of Boca, which includes a center for clinical research. He received a BS in neuroscience and behavioral biology from Emory University and an MD from the University of Florida College of Medicine, where he graduated first in his class. Dr. Fromowitz completed an internship in internal medicine and a residency in dermatology and cutaneous surgery at Shands Hospital in Gainesville, Florida, serving as Chief Dermatology Resident in his final year of residency.  He is a Diplomate of the American Board of Dermatology and is a Fellow of The American Society for Lasers in Medicine and Surgery, The American Society of Dermatologic Surgery, The American Society of Mohs Micrographic Surgery and The American Academy of Dermatology.  He is a clinical affiliate assistant professor at Florida Atlantic University, Charles E. Schmidt College of Medicine.

“We highly value our relationships with leading practitioners such as Dr. Fromowitz, and are pleased to sponsor continuing education programs such as this one to broaden the knowledge of dermatologists and keep their skills sharp during this period of limited patient contact,” said Joe Sardano, Sensus Healthcare’s chief executive officer.

About the Fall Clinical Virtual Grand Rounds

The Fall Clinical Virtual Grand Rounds (FCVGR) is a new online series designed to help maintain the educational opportunities for dermatologists as if they were able to attend grand rounds in person. FCVGR consists of weekly CME sessions on a variety of dermatological diseases and tools.         

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit .            

Contact:

LHA Investor Relations

Kim Sutton Golodetz

212-838-3777




EN
24/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SENSUS HEALTHCARE

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide...

Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits BOCA RATON, Fla, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, has partnered with Pompano Veterinary Oncology to pione...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Resul...

REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer’s request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more tha...

 PRESS RELEASE

Sensus Healthcare Reports Third Quarter 2024 Financial Results With Re...

Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company spe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch